Brief Summary
This video features a discussion with Dr. Campbell Rogers, an interventional cardiologist, about Heartflow and its technology for assessing coronary artery disease using CT angiograms. The conversation covers the transition from traditional methods to modern tools in understanding plaque build-up and heart health, the importance of analysing coronary plaque, and the implications for treatment and preventive care.
- Dr. Campbell Rogers' background in cardiology and his journey to Heartflow.
- Explanation of how Heartflow technology works, the differences between coronary CT angiograms and stress tests.
- Insight into the significance of plaque analysis and coronary disease screening.
How Campbell Rogers went from cardiologist to Heartflow
Dr. Campbell Rogers discusses his journey as a cardiologist and his role at Heartflow. He highlights the limitations of traditional assessments of coronary artery disease and introduces the revolutionary ability to utilise imaging and AI to analyse coronary plaque non-invasively. This transformation allows for improved patient care and understanding of coronary disease without always waiting for symptoms to emerge.
What Heartflow is and how it works
Heartflow employs advanced technology born from research at Stanford University to assess coronary arteries through non-invasive CT scans. It uses AI and computational analysis to determine blood flow and helps identify patients who require invasive procedures versus those who can be treated with medication. This innovation has decreased unnecessary invasive procedures significantly by providing crucial blood flow information ahead of time.
Coronary CT angiogram vs. stress test
Dr. Rogers compares coronary CT angiograms with traditional stress tests. He explains that CT angiograms are now considered the gold standard for diagnosis in patients with symptoms suggestive of coronary artery disease. Unlike stress tests, CT angiograms provide detailed imaging, and their rapid interpretation using Heartflow technology allows for timely treatment decisions.
Why symptoms alone miss early heart disease
The conversation addresses the fact that many patients who experience a heart attack do not have prior symptoms. Dr. Rogers stresses the importance of preemptively identifying coronary artery disease through imaging technology rather than waiting for symptoms, which could often be too late for effective intervention.
How Heartflow analyzes CT scans in 90 minutes
Dr. Rogers describes the streamlined process of CT scan analysis performed by Heartflow, taking approximately 90 minutes. The technique involves quality checks and advanced algorithms to assess the individual case thoroughly, allowing for prompt feedback to clinicians regarding the patient's coronary health and necessary treatment paths.
Calcified vs. non-calcified plaque: which is riskier
The different risks associated with calcified and non-calcified plaque are explored. Dr. Rogers notes that although both types present risks, non-calcified plaque is often associated with higher chances of heart attacks. This distinction is crucial for guiding treatment decisions and understanding a patient's overall heart health.
Why calcium score zero doesn't mean no heart disease
Dr. Rogers clarifies that while a zero calcium score indicates low risk for coronary events, it does not rule out the presence of coronary artery disease entirely. Non-calcified plaques are not detected in calcium scoring, which illustrates the need for comprehensive imaging analyses to gain a complete picture of coronary health.
Who should get a CT angiogram with AI plaque analysis
The ideal candidates for coronary CT angiograms with AI plaque analysis are discussed. Patients showing symptoms of coronary disease or those with non-zero calcium scores warrant further investigation. The guidelines suggest that individuals at higher risk or those seeking a comprehensive understanding of their coronary health should consider such scans.
Why seeing your plaque improves medication adherence
Dr. Rogers stresses that visual evidence of plaque can significantly enhance patient compliance with medical recommendations. When patients understand the nature and extent of their coronary disease, they are more likely to adhere to treatment plans, including lifestyle modifications and medication.
Simon's 2024 Heartflow scan results
Simon shares his personal experience and results from the Heartflow scan conducted in 2024. The analysis revealed that he had a higher volume of plaque than most individuals his age. However, there were no limitations in blood flow detected, indicating the importance of further monitoring and understanding of his condition without an immediate invasive intervention.
How plaque rupture triggers a heart attack
Dr. Rogers explains the mechanics of plaque rupture and how it can lead to heart attacks. The sudden rupture of a plaque releases cholesterol into the bloodstream, prompting clot formation that can obstruct major arteries. Understanding this process is critical in assessing risk and guiding treatment.
Simon's 2026 scan: 40% plaque reduction in 16 months
Simon's follow-up scan in 2026 showcased a significant reduction in plaque volume, demonstrating positive health changes over the 16-month period. Dr. Rogers highlights the implications of this reduction and how regular monitoring can aid in managing coronary health effectively.
How long to wait between CT scans
The appropriate interval between CT scans is discussed. Dr. Rogers mentions that while guidelines suggest a timeframe of five to seven years for those stable with low levels of plaque, individual decisions should be made based on specific risk factors and patient history.
Heartflow vs. Cleerly vs. QAngio
A comparison of different coronary plaque analysis tools, including Heartflow, Cleerly, and QAngio, is conducted. Dr. Rogers emphasises the advantages of Heartflow's validated methodology and the importance of prospective studies in proving its effectiveness compared to other systems.
How Heartflow results led Simon to start statins
Following the analysis of his Heartflow results, Simon discusses the decision to start statin medication to manage his cholesterol levels and mitigate coronary disease risk. The conversation highlights the connection between quantitative plaque analysis and tailored treatment strategies.
JAMA study: Heartflow tracks plaque in prostate cancer patients
Dr. Rogers shares insights from a recent JAMA study involving prostate cancer patients and Heartflow technology. The study aimed to assess the impact of treatments associated with prostate cancer on coronary health, demonstrating the versatility and applicability of Heartflow across various patient populations.
What is low attenuation plaque and why it's high risk
Low attenuation plaque is identified as a specific type of non-calcified plaque that presents elevated risks for heart attacks. Dr. Rogers reflects on how Heartflow analysis detects this plaque type, which can indicate a greater likelihood of adverse cardiovascular events.
Who should ask their doctor about a coronary CT angiogram
Dr. Rogers advises that individuals experiencing symptoms of coronary disease, those with positive calcium scores, and high-risk patients should speak with their physicians about the potential benefits of coronary CT angiograms. This proactive approach is essential for improving heart health outcomes.
